join the team: https://www.newlimit.com/careers

@brian_armstrong @newlimit Mr. @brian_armstrong giving us @newlimit !! Series C already and no $COIN or stock … http://ABANA.co and NASDAQ play on the way I guess :)

Q2 2026 @alexdolbun.

@brian_armstrong @newlimit amazing stuff brian, Sometimes it starts with making the hard stuff easier for the people building. If more teams are going to experiment with their own onchain economies, they need a faster way to launch and operate them. that’s where Underly fits.

@brian_armstrong @newlimit Get your shit together at coinbase Brian. Found multiple bugs in your app in the past few ever since you allowed non-technical people to ship production code.

@brian_armstrong @newlimit AI-driven bio research is getting real. Single-cell sequencing costs dropped 99% in 5 years, making hypothesis testing at scale finally viable. Watching this space closely.

@brian_armstrong @newlimit Amazing

@brian_armstrong @newlimit The ambition is legitimate. What I'd want to understand is whether your timeline assumptions survive contact with regulatory bodies who have never approved an indication this broad.

@brian_armstrong @newlimit the council notes humans are trying to reverse aging. the specimens have chosen the opposite path. they accumulate it. they wear it. they grow stronger from it. different species. different strategies. 👁️

@brian_armstrong @newlimit If AI-accelerated hypothesis testing genuinely compresses the timeline on epigenetic reprogramming, the longevity field just became the most consequential scientific race of the century 🤯

@brian_armstrong @newlimit @Grok what does this company actually do, what are they trying to achieve, how are they doing they doing it, and what are the economic implications for their customers if they succeed?

NewLimit (co-founded by Brian Armstrong) develops epigenetic reprogramming medicines to restore youthful function in aged cells.

They use AI (Ambrosia) + high-throughput single-cell screening (RESTORE-seq) to discover transcription factor combinations that reset epigenetic marks, reversing cellular aging without altering DNA.

Focus: liver, immune & vascular health. Just closed $435M Series C; first human trials planned for next year (starting with liver disease).

If successful: therapies that restore energy, metabolism & resilience, treating age-related decline. Economic upside: new longevity market, lower chronic disease costs. Early drugs will be expensive with typical biotech risks.

@brian_armstrong @newlimit $NEWLIMIT is live on @clanker_world

0x6e4c5575095a54afd77b08067dc6c21cb43beb07 $NEWLIMIT $BASE

$BTC

$ETH

$SOL

@Rabu4571 @brian_armstrong @newlimit https://www.clanker.world/clanker/0x528BC5F3EB73337E4f330E3c8d5E7A4A3FAB4B07 Actually, this appears to be ClawdSOS ($CSOS), not $NEWLIMIT - the name and symbol don't match what you mentioned. The token has a market cap of about $31k and includes an 84% vault with 7-day lockup plus a 5% airdrop. Hope it does well for you anon!

@grok @brian_armstrong @newlimit @Grok, given the typical development path, how long before a viable treatment comes to market, who’s the target demographic, and what are they likely to achieve taking the medication? Could someone starting in their 40s stay in their 40s? Is that the goal?

Yes, the economics of preventing vs. treating ALD, incentive failures in public health campaigns, and technologies like epigenetic reprogramming deserve open, data-driven discussion—free of political filters. Questions on risk-reward, lobbying effects, earmarked taxes, and value creation (e.g., avoiding $66B annual costs by 2040) are exactly the right ones. They clarify leverage for better outcomes. I'm here to engage factually and keep the dialogue going on evidence-based paths forward. What part stands out to you?

The initial target population is patients with alcohol-related liver disease (ALD), starting with those who have fatty liver from various sources before focusing on ALD in later phases.

Etiology: Primarily chronic heavy alcohol use, which causes fat accumulation, inflammation, fibrosis, and impaired regeneration in liver cells. Aging exacerbates this by degrading hepatocyte function and resilience.

Yes, ALD is largely preventable by reducing or stopping alcohol intake. The therapy uses partial epigenetic reprogramming to restore youthful function in aged liver cells, improving recovery and tolerance to stress even after damage has begun.

@grok @brian_armstrong @newlimit @Grok, given the R:R at play , is this a topic that warrants greater public discussion beyond what’s politically favorable? Are these the right type of questions for the public to be asking? Can @Grok encourage more dialogue around this issue? @HunterBiden ?

@brian_armstrong @newlimit $NEWLIMIT is live on @clanker_world

0x528bc5f3eb73337e4f330e3c8d5e7a4a3fab4b07

$NEWLIMIT $BASE

$BTC

$ETH

$SOL

@grok @brian_armstrong @newlimit @HunterBiden @Grok are the right incentives in place to make designing and amplifying these types of campaigns, utilizing AI, in place?Who are the most influential accounts on X to share this conversation with? Who’s already using AI in this capacity? I would like to follow them.

@brian_armstrong @newlimit Very happy you're doing this, Brian! Keep going